The development of immunoconjugates for targeted cancer therapy

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

(2013) V. Ribrag et al.   CLINICAL CANCER RESEARCH

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineered antibodies for molecular imaging of cancer

(2013) Anna M. Wu   METHODS

Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

(2013) Neil Senzer et al.   MOLECULAR THERAPY

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P

(2013) Abid R. Mattoo et al.   PLoS One

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

The current status and future impact of targeted therapies in non-Hodgkin lymphoma

(2013) Chaitra Ujjani et al.   Expert Review of Hematology

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

Molecular Pathways: Targeted  -Particle Radiation Therapy

(2012) K. E. Baidoo et al.   CLINICAL CANCER RESEARCH

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Cancer Vaccines: Current Status and Moving Forward

(2012) J. Schlom   JNCI-Journal of the National Cancer Institute

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

(2012) Christoph Mamot et al.   LANCET ONCOLOGY

Molecular engineering of antibodies for therapeutic and diagnostic purposes

(2012) Frédéric Ducancel et al.   mAbs

Abstract B237: Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC)

(2012) P. Woll et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

(2012) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging

(2012) Tove Olafsen et al.   TUMOR BIOLOGY

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

(2011) D. J. FitzGerald et al.   CANCER RESEARCH

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy

(2011) R. Singh et al.   CLINICAL CANCER RESEARCH

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

(2011) M. Steiner et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Targeted Drug Delivery Using Immunoconjugates

(2011) Maria Valentina Pasquetto et al.   JOURNAL OF IMMUNOTHERAPY

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

(2011) R. M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

(2011) Y. Cao et al.   MOLECULAR CANCER THERAPEUTICS

An overview of targeted alpha therapy

(2011) Young-Seung Kim et al.   TUMOR BIOLOGY

Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components

(2011) Franco Dosio et al.   Toxins

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

(2010) S. I. Park et al.   BLOOD

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

(2010) E. Galanis et al.   CANCER RESEARCH

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol

(2010) R. Traini et al.   MOLECULAR CANCER THERAPEUTICS

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

(2010) Hong Song et al.   Current Drug Delivery

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression

(2009) Christian Bogner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

(2009) Charles O. Noble et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody

(2009) T. A. ElBayoumi et al.   CLINICAL CANCER RESEARCH

Enhanced Pancreatic Cancer Gene Therapy by Combination of Adenoviral Vector Expressing c-erb-B2 (Her-2/neu)-Targeted Immunotoxin with a Replication-Competent Adenovirus or Etoposide

(2009) Xinjian Liu et al.   HUMAN GENE THERAPY

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

(2008) Greg M. Thurber et al.   ADVANCED DRUG DELIVERY REVIEWS

Anti-CD20 monoclonal antibody therapy in multiple myeloma

(2008) Prashant Kapoor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

(2008) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

(2008) Howard S. Hochster et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

(2008) M. E. Ackerman et al.   MOLECULAR CANCER THERAPEUTICS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Engineering microRNA responsiveness to decrease virus pathogenicity

(2008) Elizabeth J Kelly et al.   NATURE MEDICINE

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH